Navigation

Roche wins EU approval for cancer drug

Roche's research centre in Basel Keystone Archive

The Swiss pharmaceutical giant, Roche, has been given the green light by the European Commission for its Xeloda drug - the first oral treatment for metastatic colorectal cancer.

This content was published on February 12, 2001 - 10:57

In a statement, the Basel-based pharmaceutical group said Xeloda would be more effective than current treatments and easier for patients to take than intravenous chemotherapy.

The EU's backing follows two controlled tests involving 1200 patients. The drug is already approved for this use in many countries including Switzerland, Canada and Australia.

It's also used in the fight against breast cancer in more than 50 countries.

swissinfo with agencies

This article was automatically imported from our old content management system. If you see any display errors, please let us know: community-feedback@swissinfo.ch

Comments under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

Share this story

Join the conversation!

With a SWI account, you have the opportunity to contribute on our website.

You can Login or register here.